Please join Rich Bendis on Thursday, February 6th, 2014 for the 7th Annual Health IT Day in Annapolis. Learn more about Health Information Technology (HIT) and how it affects you as a consumer today and in the future. Get the chance to meet with district legislators and senators to let them know what needs to be done to further push HIT in Maryland and keep us on the cutting edge of this rapidly evolving field.
The Portfolio Director is a senior licensing professional within the office of Johns Hopkins Technology Transfer (JHTT) who is responsible for managing a portfolio of invention. A Portfolio Director will manage a team of licensing professionals and provide scientific, intellectual property, licensing and marketing expertise, mentorship, team building for members working within the portfolio and across portfolios, educational outreach, relationship management, organizational and communication skills to commercialize inventions resulting from research at Johns Hopkins University. This position reports to the JHTT Executive Director.
Work closely with the CEO, as well as other members of Brace’s management team on developing and implementing scientific and corporate strategy;
With assistance from the management team, oversee and add value to the day-to-day efforts of Brace, especially business development activities, general business issues, marketing analyses, technology implementation, and other functions;
Identify investment opportunities which fit the strategy of Brace Pharmaceuticals;
Coordinate and perform due diligence of potential investment opportunities and execute the transactions;
Control and follow up the Brace investments to ensure that the agreed objectives are met and business is performed within the established guidelines;
Draft analyses for submission to CEO and Directors;
Prepare scientific and business presentation for the company;
Assist in the recruitment of staff, including assistants and managers;
Help maintain new strategic partnerships, scientific collaborations, and investor relationships;
Assist with technology licensing efforts and help Brace advance programs;
Act as a public relations person for Brace Pharmaceuticals, and represent Company in events and conferences;
Desired Skills and Experience
Minimum 10 years working with pharmaceutical industry.
Strong experience in evaluation, diligence and deal execution of pharmaceutical projects in development stage.
VC and Investment Banking experience.
Formation in medicine, chemistry, biologics or pharmaceuticals.
The incumbent will be responsible for commercializing inventions made as a result of the research conducted at UMBC. Specific duties includes: evaluating invention disclosures for patentability and commercial potential; making recommendations regarding the filing of patent applications; securing intellectual property protection by filing provisional applications and working with outside counsel to file and maintain utility for selected disclosures; marketing intellectual property to find companies interested in taking a license; negotiating license agreements and other technology commercialization activity; developing business plans and other commercialization strategies for UMBC inventions; advising faculty, students, and staff on intellectual property matters; educating faculty about the technology transfer process; working to ensure compliance with research agreements, federal guidelines, and other obligations that UMBC has with respect to inventions created as part of UMBC’s research enterprise; and performing other duties as assigned by the Director of OTD.
Minimum Qualifications
Requires a Bachelor’s degree in engineering or computer science and one year of experience in commercialization of physical/information science technology. Previous university-based experience in licensing or business development or similar experience in an industry, government or academic setting strongly desired. Working knowledge of federal and state laws regarding intellectual property and technology transfer process preferred.
Salary
Salary is commensurate with qualifications and experience.
Application
For best consideration, submit a cover letter with salary requirements, resume, and contact information for three professional references by February 24, 2014 (resumes will be accepted until filled) to Wendy Martin: wmartin@umbc.edu
The Director, AMS provides overall leadership, management, coordination and strategic direction for the ATCC Microbiology Systems business unit of ATCC. AMS is focused on the development of innovative products and reference standards for use in microbiological-based infectious disease research and industrial applications. As a member of the ATCC Senior Management Team the Director, AMS will also have a direct impact on the management of the ATCC organization. The incumbent is responsible for AMS on a P&L basis and will work cross-functionally within ATCC to ensure that business unit revenue goals are met. This position is also accountable for setting developmental program initiatives, creating external partnerships that facilitate ATCC as a go-to partner for biodeposit and standards development, and implementing programs to deliver on agreed objectives for the AMS business unit. The Director, AMS is responsible for the overall success of the product development process within the AMS business unit including the on-time, on-target and on-budget launch of new products. The incumbent actively supports, complies with and enforces all ATCC corporate policies and procedures.
The Vice President, Operations will provide leadership, direction and oversight to the manufacturing, inventory/repository and distribution of cultures and other biological products. This position will participate in ATCC’s strategic planning process. The Vice President oversees the management of the facilities, engineering, materials management, and planning operations. The Vice President ensures ATCC maintains robust and compliant Quality Assurance, Regulatory Compliance and Laboratory Testing Services operations. As a member of the Senior Management Team, this individual will participate in the annual strategic planning and budgeting processes, as well as regular management meetings. The incumbent actively supports, complies with and enforces all ATCC corporate policies and procedures.
For the first time, Montgomery College and industry giant Lockheed Martin join together to meet the nation’s growing demand for cyber security professionals. Register now to benefit from this exciting partnership where you will learn from the industry’s leading experts in secure software development.
Epidarex Capital, a leading international early-stage life science venture capital fund, has announced a £4 million Series A investment, in Edinburgh Molecular Imaging (EMI). Scottish Enterprise’s investment arm, the Scottish Investment Bank, also participated in the round. EMI, an Edinburgh BioQuarter spin-out company from the University of Edinburgh, is developing a pioneering Optical Molecular Imaging (OMI) technology with the potential to address unmet needs in the diagnosis and monitoring of several major diseases.
EMI’s highly innovative OMI technology revolves around the development of fluorescent imaging reagents that detect harmful processes deep inside the human body, at the bedside, in real time and at molecular resolution. The company’s initial focus is on lung conditions but the technology is applicable to a wide spectrum of disease. The company’s approach has the potential to transform clinicians’ ability to diagnose and manage a number of serious respiratory conditions, including lung cancer, fibrosis, lung infections and acute respiratory distress syndrome (ARDS). EMI’s technology will address the pressing need for tests which can rapidly provide diagnostic certainty and reduce healthcare costs. Respiratory diseases kill one in five people in the UK and cost the NHS over £6 billion per year, with lung cancer being the biggest cancer killer.
Mobile technology is transforming the way patients and doctors interact.
That was the message conveyed by a panel of speakers at a Health IT Forum hosted at Johns Hopkins University’s Montgomery County Campus.
The Health IT Forum series, held four times a year, is a community partnership co-sponsored by the Montgomery County Department of Economic Development, the TechCouncil of Maryland and the Montgomery County Chamber of Commerce. The January forum, titled “Patient Tools for Better Health,” attracted approximately 50 health IT experts from the region.
New Enterprise Associates has stepped up to help with a $14 million A round designed to get Austin, TX-based startup Lumos Pharmaceuticals in the clinic with a new therapy for an autism spectrum disorder characterized by severe cognitive impairment. Sante Ventures negotiated the original term sheet for Lumos and NEA joined the financing later.
Lumos has been working with a subsidiary of the NIH on LUM-001, an analogue of creatine that was studied by investigators at the University of Cincinnati. The “repurposed” molecule has been shown in animal studies to cross the blood-brain barrier, offering the potential to restore levels of creatine in the brain, which is eliminated by a defect in the transporter gene found in people who suffer from a range of cognitive disorders, including autism.
On Tuesday, Kaiser Permanente and the Veterans Health Administration announced that they will collaborate to research and develop best practices for various health care fields, EHR Intelligence reports (Freeman, EHR Intelligence, 2/4).
The partnership is part of the VA’s Innovation Partnership Program.
Bethesda Blues and Jazz – 7719 Wisconsin Avenue, Bethesda, MD 20814
What’s next for Montgomery County? The potential for livable work, live and play environments on Metro abound. But what about the business community? What is it going to take to build an innovation economy? Is Montgomery County going to become the next tech hub?
Join us for a very special morning event featuring some of the brightest and most influential business and real estate leaders as they discuss some of the most dramatic decisions that this region will face in the upcoming year. Sign up now to join leaders of the Maryland business region for an important morning of discussion and networking!
BioHealth Innovation, Inc. (BHI), a Montgomery County, Maryland innovation intermediary which translates market-relevant research into commercial success by bringing together among other things management, funding, and markets, is seeking an experienced life science professional with entrepreneurial experience to serve as its Entrepreneur-in-Residence (EIR) financially supported by the China Fortune Land Development Company, LTD (CFLD), focused on advancing China-U.S. partnerships. The EIR will collaborate with a life science commercialization expert who has an interest in relocating to the Peptide Valley to assist CFLD in Chinese life science commercialization. BHI will work with the CFLD EIR on this recruitment as well as provide training to them. The EIR will lead in the scouting of technologies in both markets with a preliminary focus on therapeutic vaccines, antibodies, medical devices, proteins and peptides and diagnostics. Further, the EIR will build partnerships in life science hubs in the U.S. and China which support the progression of these technologies for manufacturing or at the preclinical testing stage of development, the primary focus of the Peptide Valley. This EIR will evaluate life science technologies in both markets, provide a strategic plan for start-up companies, advise on opportunities for new ventures, and lead the commercial strategy for mature assets. The EIR will oversee primary and secondary research and will provide strategic recommendations and insights on the direction of potential assets that have potential for Chinese commercialization in the Peptide Valley or other CFLD research parks.
Ten big rival drug companies have formed a pact to cooperate on a government-backed effort to accelerate the discovery of new drugs, the Wall Street Journal reported.
The companies and the National Institutes of Health (NIH) will share scientists, tissue and blood samples, and data, to identify targets for new drugs for diseases such as Alzheimer’s, Type 2 diabetes, rheumatoid arthritis and lupus, the Journal said.
TechConnect is pleased to host 2014 TechConnect World, June 15-19 in Washington DC. The event, co-located with the 2014 National Innovation Summit the 2014 National Small Business Innovation Research (SBIR) Conference, delivers the world’s largest showcase and accelerator for industry-vetted emerging-technologies ready for commercialization.
Don’t miss this opportunity to place your technology, your company, or your agency’s awardee portfolio into the TechConnect Innovation Showcase and Accelerator program to be matched with the world’s largest gathering of potential investment and corporate partners.
HHS is committed to implementing all the provisions of the SBIR/STTR Reauthorization Act of 2011 (P.L. 112-81). NIH has set up a website to keep the small business research community abreast of its implementation plan for the many changes resulting from the reauthorization. The site will be updated as the implementation process moves forward.
This issuance implements an additional provision of the Reauthorization Act.
It’s nearly Valentine’s Day. And for humans, love is in the air. But it’s a good time to examine how love is in the air for crabs, too, and how their mating affects a Maryland industry.
For blue crabs, it’s all about the pheromones in the water. And for female crabs looking for mates, size really does matter.
An untraceable currency called Zerocoin is being designed by Johns Hopkins University researchers to compete with other virtual moneys such as Bitcoin. The researchers say that if virtual currencies are going to exist, there should be one that provides the same kind of privacy that people have when exchanging traditional forms of money.
Inside a drab computer lab at Johns Hopkins University, a team of researchers is trying to build something that has never existed before: a digital currency that changes hands completely in secret. Its name is Zerocoin.
Ozarks Medical Center in Missouri and Flagstaff Medical Center in Arizona are just two hospitals in 25 states across the country that will receive federal funding for telemedicine projects. Agriculture Secretary Tom Vilsack announced nearly $16 million in USDA grants would be disbursed for distant learning and telemedicine services.
The USDA’s Distance Learning and Telemedicine Loan and Grant program provides funding to rural hospitals, clinics, schools and libraries for equipment and technical assistance for telemedicine and distance learning. Grant recipients must demonstrate that they serve rural America, prove there is an economic need and provide at least 15 percent in matching funds.
Frustrated by unpredictable and often political funding for science research, a handful of young researchers think they’ve found the answer: crowdfunding.
Jackson Solway Experiment.com Co-founder and CEO Cindy Wu The researchers–who have backgrounds in synthetic biology, rocket science and other disciplines–built much of their startup, Experiment.com, while at the Y Combinator accelerator in 2013.
“Our goal is absolutely to democratize knowledge,” says Denny Luan. “Modern science has such a rush for fast results – publish or perish, output over process. We’d like to show the greater public that science does not have to be locked up behind monasterial walls. We’d like to change the way science is shared – in an engaging, deliberately beautiful way. Real-time, open-access and with great design.”
Luan is co-founder of what, until this morning, was known as “Microryza” – the site has been renamed “Experiment” as part of a revamped branding strategy – a potentially revolutionary crowdfunding platform that is looking to do for science what Kickstarter has done for the entertainment industry.
As part of an ongoing effort to empower patients to be informed partners with their health care providers, the Department of Health and Human Services (HHS) has taken action to give patients or a person designated by the patient a means of direct access to the patient’s completed laboratory test reports.
“The right to access personal health information is a cornerstone of the Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule,” said Secretary Kathleen Sebelius. “Information like lab results can empower patients to track their health progress, make decisions with their health care professionals, and adhere to important treatment plans.”
Four years ago Congress created a new Center for Medicare and Medicaid Innovation as part of its Patient Protection and Affordable Care Act. The Innovation Center’s purpose was “to test innovative payment and service delivery models to reduce program expenditures… while preserving or enhancing quality of care.” Congress has allotted $10 billion to support the Innovation Center for its first ten years of existence and additional rounds of billions for subsequent decades. The Center has long been considered one of the most important initiatives for changing broken payment models in healthcare.
Today the CMS Innovation Center categorizes its work into several key categories, including accountable care, bundled payments for care improvement, primary care transformation, initiatives focused on the Medicaid and CHIP population, and initiatives focused on Medicare-Medicaid enrollees. The remaining two areas of focus for the center are “initiatives to speed the adoption of best practices” and “initiatives to accelerate the development and testing of new payment and service delivery models.”
Independence Blue Cross today announced it has created the Independence Blue Cross (IBC) Center for Health Care Innovation, an important milestone in the company’s groundbreaking efforts to transform the Philadelphia area into a national magnet for health care innovation. At the 5,000-square foot center at 1700 Market Street in Philadelphia, the company’s associates and external partners will innovate, collaborate, and implement path-finding new concepts in health care. The center will also be the home for the company’s widening range of innovation initiatives, including its partnership with Penn Medicine and DreamIt Ventures on the region’s first health care accelerator, DreamIt Health Philadelphia, which last year brought ten promising health care startups from across the country to Philadelphia and today eight are still located in the region.
“Through the IBC Center for Health Care Innovation, we are championing health care entrepreneurism in our region, and acting as a catalyst for innovations that lead to superior care at lower costs,” said Independence Blue Cross President and CEO Daniel J. Hilferty. “With our region’s active investment community, experienced health care talent, world class health care systems, and strong academic institutions, we have all the ingredients to become the Silicon Valley of health care innovation.”
The Salk Institute’s Office of Technology Development (OTD) is responsible for managing the intellectual property of the Salk Institute.
At the OTD, our mission is to enable our researchers to realize the commercial potential of their ideas. Our goal is to develop and support relationships with industry partners who can help turn scientific progress in the lab into tangible products for the benefit of patients and society at large, while returning income to the inventor and to the Institute to support further research.
One of the old saws in journalism is to “follow the money” when you’re looking for a story. But sometimes you learn even more by following the people.
The people, in this case, are biotech venture capitalists. Regular readers of this column know that biotech VC has been going through a historic shakeout the last few years. The institutional investors who back VCs have gotten fed up with the long investment timelines, high degree of risk, and limp returns from this group of well-compensated asset managers. Not surprisingly, many VC firms have been unable to continue to raise new funds, and have turned into zombies.
A high sugar diet greatly increases the risk of cardiovascular disease regardless of body weight, according to a new study by the American Centers for Disease Control and Prevention.
The study, which is the biggest one of its kind to date and has included more than 10,000 people followed for up to 14.6 years, concludes that people who drink, for example, one soft drink per day increase their risk of cardiovascular disease by one-third.
Malcolm Gladwell opened his healthcare talk with a joke. Confessing that he is expert in neither healthcare nor interoperability, the long-time journalist revealed that he had actually pondered how his former self would cover his present self as a speaker — likely with “quotes out of context and something really snarky.”
The best-selling author and New Yorker staffer likened the change required for healthcare to make it over the interoperability hurdle to several events of this generation, “three lessons in culture, framing and consequence,” as he put it during Health Care Innovation Day.
Every month in the Startup Index, we publish a list of the startup stories that got the most attention. Scroll down to the end of the report to find this list. There is usually a common thread among the companies in the list – geography, focus, industry sector. This month the list is all over the place:
Three of the University of Pennsylvania’s health-related research centers have teamed up to launch an innovative grant program designed to lure academic investigators out of their insular comfort zones into large scale interdisciplinary research projects.
The three—Penn’s Center for Clinical Epidemiology and Biostatistics (CCEB), Leonard Davis Institute of Health Economics (LDI) and Center for Public Health Initiatives (CPHI)—are offering a novel funding structure they hope will pull together researchers from a variety of disciplines to focus on “big ideas” related to improving the health of populations.
It’s no big secret that the vast majority of venture capitalists are men. But that vastness is even a bit larger than I had expected.
Following yesterday’s news that Jennifer Fonstad and Theresia Gouw were stepping down as partners with DFJ and Accel Partners, respectively, in order to launch their own firm, we decided to begin researching exactly how many partner-level female VCs there really were.
BioHealth Innovation (BHI) is a regionally-oriented, private-public partnership functioning as an innovation intermediary focused on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in Maryland.
The information contained in this website and newsletters is for general information purposes only. The information is provided by BioHealth Innovation via its newsletters, but not written or endorsed in any way by BioHealth Innovation unless otherwise noted. While we endeavor to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
Please join Rich Bendis on Thursday, February 6th, 2014 for the 7th Annual Health IT Day in Annapolis. Learn more about Health Information Technology (HIT) and how it affects you as a consumer today and in the future. Get the chance to meet with district legislators and senators to let them know what needs to be done to further push HIT in Maryland and keep us on the cutting edge of this rapidly evolving field.
Job description
The incumbent will be responsible for commercializing inventions made as a result of the research conducted at UMBC. Specific duties includes: evaluating invention disclosures for patentability and commercial potential; making recommendations regarding the filing of patent applications; securing intellectual property protection by filing provisional applications and working with outside counsel to file and maintain utility for selected disclosures; marketing intellectual property to find companies interested in taking a license; negotiating license agreements and other technology commercialization activity; developing business plans and other commercialization strategies for UMBC inventions; advising faculty, students, and staff on intellectual property matters; educating faculty about the technology transfer process; working to ensure compliance with research agreements, federal guidelines, and other obligations that UMBC has with respect to inventions created as part of UMBC’s research enterprise; and performing other duties as assigned by the Director of OTD.
The Director, AMS provides overall leadership, management, coordination and strategic direction for the ATCC Microbiology Systems business unit of ATCC. AMS is focused on the development of innovative products and reference standards for use in microbiological-based infectious disease research and industrial applications. As a member of the ATCC Senior Management Team the Director, AMS will also have a direct impact on the management of the ATCC organization. The incumbent is responsible for AMS on a P&L basis and will work cross-functionally within ATCC to ensure that business unit revenue goals are met. This position is also accountable for setting developmental program initiatives, creating external partnerships that facilitate ATCC as a go-to partner for biodeposit and standards development, and implementing programs to deliver on agreed objectives for the AMS business unit. The Director, AMS is responsible for the overall success of the product development process within the AMS business unit including the on-time, on-target and on-budget launch of new products. The incumbent actively supports, complies with and enforces all ATCC corporate policies and procedures.
